Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05805501 · ClinicalTrials.gov registry record · Phase 2
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
A Phase 2 study of Renal Cell Carcinoma, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 2
- Development phase
- 199
- Enrollment target
- 20
- Study locations
NCT05805501: Active Phase 2 study of Renal Cell Carcinoma, sponsored by Hoffmann-La Roche.
NCT05805501 is a Phase 2 study of Renal Cell Carcinoma that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 199 participants, below the 241-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (17% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05805501, a Phase 2 study of Renal Cell Carcinoma, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 199 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the safety of tobemstomig (RO7247669) in combination with axitinib alone or with tiragolumab (anti-TIGIT) and axitinib as compared to pembrolizumab and axitinib in participants with previously untreated, unresectable locally advanced or metastatic clear-cell renal cell carcinoma (ccRCC).
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Axitinib
- DRUG Tiragolumab
- DRUG Tobemstomig
Study Locations (20)
Other
- Peking University First Hospital - Beijing
- Beijing Cancer Hospital - Beijing
- Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School - Nanjing
- Tianjin Cancer Hospital - Tianjin
- Institut Sainte Catherine - Avignon
- CHU Besançon - Hôpital Jean Minjoz - Besançon
- CHU de Bordeaux - Groupe Hospitalier Saint-André - Hopital Saint-Andre - Bordeaux
- Centre Francois Baclesse - Caen
- Centre Leon Berard - Lyon
- Institut Gustave Roussy - Villejuif
- Universitätsklinikum "Carl Gustav Carus" - Dresden
Tennessee
- SCRI Oncology Partners - Nashville
- Vanderbilt University Medical Center - Nashville
Alabama
- University of Alabama at Birmingham - Birmingham
California
- UC Irvine Medical Center - Orange
District of Columbia
- Sibley Memorial Hospital - Washington D.C.
Georgia
- Emory University - Atlanta
Maryland
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 199 participants |
| Start Date | 2023-04-21 |
| Est. Completion | 2026-10-31 |
| Phase | Phase 2 |
What the registry record for NCT05805501 still lists
NCT05805501 is an interventional study that assigns participants to a tested intervention. The registered 199 participants enrollment target is mid-sized for trials with a published cap, below the 241-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (17% lower).
The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT05805501 names 20 study sites across 9 states, led by Other, Tennessee, Alabama.
Frequently Asked Questions
What is clinical trial NCT05805501 about?
NCT05805501 is a clinical study titled "A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma". This study will evaluate the safety of tobemstomig (RO7247669) in combination with axitinib alone or with tiragolumab (anti-TIGIT) and axitinib as compared to pembrolizumab and axitinib in participants with previously untreated, unresectable locally advanced or metastatic clear-cell renal cell carci...
What is the current status of trial NCT05805501?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 199 participants. The study started on 2023-04-21. Estimated completion is 2026-10-31.
What conditions does trial NCT05805501 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma.
What interventions are being tested in trial NCT05805501?
The interventions under investigation include: Pembrolizumab (DRUG), Axitinib (DRUG), Tiragolumab (DRUG), Tobemstomig (DRUG).
Who is sponsoring clinical trial NCT05805501?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05805501 being conducted?
This trial has 20 study locations across Alabama, California, District of Columbia, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05805501's enrollment target sits among peer trials
199 30th of 121 higher than 92 of 121 other Renal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
RECRUITING · Phase 2
-
Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation
RECRUITING · Phase 2
-
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
RECRUITING · Phase 2
-
Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)
RECRUITING · Phase 2
-
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 2
-
A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04312126 · 199 participants
The Beneficial Effects of Naps on Motor Learning
- NCT04951622 · 199 participants · Phase 3
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- NCT06474533 · 199 participants
Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI